[1] 徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019,27(11):846-865. [2] Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis[J]. The Lancet, 2021,398(10308):1359-1376. [3] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018,69(2):406-460. [4] D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006,44(1):217-231. [5] Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol, 2006,4(11):1385-1394. [6] Liaw Y F, Sheen I S, Lee C M, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease[J]. Hepatology, 2011,53(1):62-72. [7] Cheung M, Walker A J, Hudson B E, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis[J]. J Hepatol, 2016,65(4):741-747. [8] 徐小元, 丁惠国, 李文刚, 等. 肝硬化腹水及相关并发症的诊疗指南(2017,北京)[J]. 中华胃肠内镜电子杂志, 2018(01):1-17. [9] De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. Journal of Hepatology, 2022,76(4):959-974. [10] 中华医学会肝病学分会, 中华医学会感染病学分会, 尤红, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022,15(6):401-427. [11] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022,77(6):1564-1572. [12] Aravinthan A D, Barbas A S, Doyle A C, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study[J]. Transplant International, 2017,30(11):1140-1149. [13] Pose E, Torrents A, Reverter E, et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement[J]. Journal Of Hepatology, 2021,75(2):275-283. [14] Hofer B S, Simbrunner B, Hartl L, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int, 2023,43(10):2220-2231. [15] Li M, Zong Z, Xiong X, et al. Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy[J]. Frontiers in Cellular and Infection Microbiology, 2023,12:1053608. [16] Liaw Y F, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study[J]. Hepatology, 2011,54(1):91-100. [17] Kim T H, Um S H, Lee Y S, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy[J]. Aliment Pharmacol Ther, 2022,55(1):83-96. [18] 阮佳佳, 温世飞, 王霞, 等. 首次失代偿期乙型肝炎肝硬化患者获得再代偿的影响因素分析[J]. 临床肝胆病杂志, 2022,38(8):1796-1800. [19] 姜绍文, 章正兰, 谢青. 失代偿期肝硬化的新定义[J]. 肝脏, 2022,27(12):1340-1343. [20] 中华医学会肝病学分会, 中华医学会感染病学分会, 魏来, 等. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022,15(6):428-447. [21] Belli L S, Berenguer M, Cortesi P A, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study[J]. J Hepatol, 2016,65(3):524-531. [22] Gentile I, Scotto R, Coppola C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort)[J]. Hepatol Int, 2019,13(1):66-74. [23] Belli L S, Berenguer M, Cortesi P A, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study[J]. J Hepatol, 2016,65(3):524-531. [24] Romano J, Sims O T, Richman J, et al. Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients[J]. JGH Open, 2018,2(6):317-321. [25] Verna E C, Morelli G, Terrault N A, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: real-world experience from HCV-TARGET cohort[J]. J Hepatol, 2020,73(3):540-548. [26] Xu X, Wang H, Zhao W, et al. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study[J]. BMJ Open, 2021,11(6):e43083. |